Novel synthesis of enamines by iridium-catalyzed dehydrogenation of tertiary aminesElectronic supplementary information (ESI) available: detailed experimental procedures and spectroscopic information. See http://www.rsc.org/suppdata/cc/b3/b304357f/
作者:Xiawei Zhang、Amy Fried、Spencer Knapp、Alan S. Goldman
DOI:10.1039/b304357f
日期:——
A novel route to enamines is reported, the dehydrogenation of tertiary amines catalyzed by a “pincer-ligated” iridium catalyst.
报道了一种新的获得烯胺的途径,即“三元胺在铱催化剂的“钳状配体”催化下脱氢”。
Formation of Enamines via Catalytic Dehydrogenation by Pincer-Iridium Complexes
作者:Yansong J. Lu、Xiawei Zhang、Santanu Malakar、Karsten Krogh-Jespersen、Faraj Hasanayn、Alan S. Goldman
DOI:10.1021/acs.joc.9b02846
日期:2020.3.6
lesser crowding of the di-isopropylphosphino-substituted catalysts. Experimentally determined kineticisotopeeffects in conjunction with DFT-based analysis support a dehydrogenation mechanism involving initial pre-equilibrium oxidative addition of the amine α-C-H bond followed by rate-determiningelimination of the β-C-H bond.
[EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
申请人:SEARLE & CO
公开号:WO2000031063A1
公开(公告)日:2000-06-02
A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.
A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA
wherein R
1
, R
2
, R
3
and R
4
are as described in the specification.
A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA),
wherein R1, R2, R3 and R4 are as described in the specification.